Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Petr V Krivorotko"'
Autor:
Petr V. Krivorotko, Yana I. Bondarchuk, Roman V. Donskih, Elena K. Zhiltsova, Nikolay S. Amirov, Sergey S. Bagnenko, Antonina V. Chernaya, Roman S. Pesotskiy, Alexander S. Emelyanov, Viktoria V. Mortada, Tengiz T. Tabagua, Larisa P. Gigolaeva, Sergey S. Yerechshenko, Alexander V. Komyakhov, Kirill S. Nikolaev, Konstantin Yu. Zernov, Diana A. Enaldieva, Alexsander A. Bessonov, Anna S. Artemyeva, Ekaterina A. Busko, Vladislav V. Semiglazov, Tatiana Yu. Semiglazova, Vladimir F. Semiglazov, Aleksey M. Belyaev
Publikováno v:
HERALD of North-Western State Medical University named after I.I. Mechnikov. 15:87-95
BACKGROUND: Surgical treatment of breast cancer plays a major role in the combined and complex treatment of patients. The purity of the examined edges of the resected breast tissue is the main indicator of the reliability of the breast-conserving sur
Autor:
Nikolay S. Amirov, Petr V. Krivorotko, Viktoria V. Mortada, Roman V. Donskikh, Roman S. Pesotskiy, Alexander S. Emelyanov, Tengiz T. Tabagua, Larisa P. Gigolaeva, Sergey S. Yerechshenko, Alexander V. Komyakhov, Kirill S. Nikolaev, Konstantin Yu. Zernov, Elena K. Zhiltsova, Yana I. Bondarchuk, Diana A. Enaldieva, Alexander A. Bessonov, Anna S. Artemyeva, Sergey N. Novikov, Ekaterina A. Busko, Tatyana Yu. Semiglazova, Vladimir F. Semiglazov, Alexey M. Belyaev
Publikováno v:
HERALD of North-Western State Medical University named after I.I. Mechnikov. 15:63-71
BACKGROUND: Neoadjuvant systemic therapy for triple-negative and HER2-positive breast cancer can achieve a complete pathologic response in approximately 60% of patients. Pathological complete response to neoadjuvant systemic therapy is a predictive f
Autor:
Diana A. Enaldieva, Roman V. Donskikh, Petr V. Krivorotko, Evgeny N. Imyanitov, Elena K. Zhiltsova, Anna P. Sokolenko, Tengiz T. Tabagua, Nikolay S. Amirov, Roman S. Pesotsky, Laysan F. Shaikhelislamova, Alexander S. Emelyanov, Viktoria V. Mortada, Larisa P. Gigolaeva, Sergey S. Yerechshenko, Alexander V. Komyakhov, Kirill S. Nikolaev, Konstantin Yu. Zernov, Yana I. Bondarchuk, Ruslan M. Paltuev, Alexander A. Bessonov, Anna S. Artemyeva, Vladislav V. Semiglazov, Tatiana Yu. Semiglazova, Vladimir F. Semiglazov, Alexsey M. Belyaev
Publikováno v:
HERALD of North-Western State Medical University named after I.I. Mechnikov. 14:33-42
BACKGROUND: BRCA-associated triple-negative breast cancer does not only have a better overall survival rate, but also a longer recurrence-free period in compatison to patients with sporadic breast cancer. BRCA-associated triple-negative breast cancer
Autor:
Ekaterina V Gubarkova, Dmitry A Vorontsov, Alexander A Sovetsky, Evgeniya L Bederina, Marina A Sirotkina, Alexandra Yu Bogomolova, Sergey V Gamayunov, Alexey Yu Vorontsov, Petr V Krivorotko, Vladimir Y Zaitsev, Natalia D Gladkova
Publikováno v:
Laser Physics Letters. 20:065601
We report the first application of compression optical coherence elastography (C-OCE) to evaluate both linear and nonlinear elastic properties of lymph nodes (LNs) for assessing their status, which is an important factor for detecting metastasis and
Autor:
Antonina V. Chernaya, Roksana H. Ulyanova, Petr V. Krivorotko, Sergey N. Novikov, Sergey V. Kanaev, Anna S. Artemieva, Lev N. Shevkunov, Stanislav A. Tyatkov, Vsevolod V. Danilov
Publikováno v:
Radiology and Medical Diagnostic Imaging. :1-6
Background: Dual-energy contrast-enhanced spectral mammography (CESM) is one of the latest methods for breast lesions characterization, where structural and functional (i.e., vascularization) assessment are combined. Nowadays an interpretation of con
Autor:
Hirotaka Iwase, Petr V. Krivorotko, Marina Moreira Costa Zorzetto, Rubi K. Li, Rajesh Aggarwal, Reginald Ewesuedo, Sachin Hingmire, Ray Li, Mark D. Pegram, Keun Seok Lee, Amy Freyman, Elizabeth Tan-Chiu, Igor Bondarenko, Charles Zacharchuk, Joanna Pikiel, Alicia M. Vana, Donghua Yin
Publikováno v:
British Journal of Cancer
Background This randomised, double-blind study compared PF-05280014 (a trastuzumab biosimilar) with reference trastuzumab (Herceptin®) sourced from the European Union (trastuzumab-EU), when each was given with paclitaxel as first-line treatment for